✦ LIBER ✦

Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial

✍ Scribed by Ragaz, J.; Olivotto, I. A.; Spinelli, J. J.; Phillips, N.; Jackson, S. M.; Wilson, Kenneth. S.; Knowling, M. A.; Coppin, C. M. L.; Weir, L.; Gelmon, K.; Le, N.; Durand, R.; Coldman, A. J.; Manji, M.

Book ID: 126925419
Publisher: Oxford University Press
Year: 2005
Tongue: English
Weight: 246 KB
Volume: 97
Category: Article
ISSN: 0027-8874
DOI: 10.1093/jnci/djh297

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Locoregional Radiation Therapy in Patien

Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial

✍ Ragaz, J.; Olivotto, I. A.; Spinelli, J. J.; Phillips, N.; Jackson, S. M.; Wilso 📂 Article 📅 2005 🏛 Oxford University Press 🌐 English ⚖ 246 KB

## Background: The british columbia randomized radiation trial was designed to determine the survival impact of locoregional radiation therapy in premenopausal patients with lymph node-positive breast cancer treated by modified radical mastectomy and adjuvant chemotherapy. three hundred eighteen pa

3–29 Locoregional Radiation Therapy in P

3–29 Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial

✍ Buchholz, T.A. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Low Risk of Locoregional Recurrence in t

Low Risk of Locoregional Recurrence in the Absence of Regional Radiation Therapy in Node-Positive Breast Cancer Patients Treated With Chemotherapy, Breast Conserving Surgery, and Adjuvant Breast Radiation Therapy

✍ Grendarova, P.; Trotter, T.; Craighead, P. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Randomized adjuvant trial to evaluate th

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization

✍ Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Kei 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b

A randomized phase III trial of adjuvant

A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study

✍ J. Andersen; M. Andersson; K.W. Andersen; P. Dombemowsky; H.T. Mouridsen; C. Ros 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 300 KB

3–36 Study of Failure Pattern Among High

3–36 Study of Failure Pattern Among High-Risk Breast Cancer Patients With or Without Postmastectomy Radiotherapy in Addition to Adjuvant Systemic Therapy: Long-term Results From the Danish Breast Cancer Cooperative Group DBCG 82 b and c Randomized Studies

✍ Chouly, Franz; Lozinski, Alexei 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB